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Abstract Although febrile urinary tract infections (UTIs)
are relatively common in adults, data on optimal treatment
duration are limited. Randomized controlled trials specifi-
cally addressing the elderly and patients with comorbidities
have not been performed. This review highlights current
available evidence. Premenopausal, non-pregnant women
without comorbidities can be treated with a 5–7d a y
regimen of fluoroquinolones in countries with low levels
of fluoroquinolone resistance, or, if proven susceptible, with
14 days of trimethoprim-sulfamethoxazole. Oral β-lactams
are less effective compared with fluoroquinolones and
trimethoprim-sulfamethoxazole. In men with mild to
moderate febrile UTI, a 2-week regimen of an oral
fluoroquinolone is likely sufficient. Although data are
limited, this possibly holds even in the elderly patients
with comorbidities or bacteremia.
Keywords Febrile urinary tract infections.Acute
pyelonephritis.Complicated urinary tract infection.
Prostatitis.Antibiotics.Fluoroquinolones
Introduction
Urinary tract infections (UTIs) are among the most
commonly encountered bacterial illnesses. In adults, UTIs
can be classified into acute uncomplicated cystitis, acute
uncomplicated pyelonephritis, complicated UTI, and
acute complicated pyelonephritis. For men, several
categories of prostatitis are distinguished [1–3]. The
term “uncomplicated” usually reflects UTIs in premeno-
pausal, non-pregnant women with no known anatomical or
functional urological abnormalities or other comorbidities
[4]. Some authors advocate to consider UTIs in postmen-
opausal women or women with well controlled diabetes
mellitus without urological sequelae also to be “uncomplicat-
ed” [2]. Given these various classifications of UTIs in the
literature, it likely makes more sense to classify these
patients uniformly according to their presentation, in which
fever reflects the presence of a parenchymal inflammation.
From a scientific point of view, it is interesting to know
whether the UTI involves the kidney, prostate, bladder, blood
circulation, lymph nodes of the pelvis or a combination of
all. But from a clinical point of view, febrile UTI should be
considered as tissue inflammation of the urinary tract,
whereas an exact anatomical distinction on clinical grounds
can often not be made. In this article, we use febrile UTI as
the clinical syndrome of interest because this is how patients
present, and fever mainly determines the appropriate
treatment. According to the above mentioned classifications,
febrile UTI includes complicated UTI with fever, acute
prostatitis, acute (un-)complicated pyelonephritis and, as has
been suggested, the urosepsis syndrome [5].
The optimal treatment duration of febrile UTI has not
been established yet, but current strategies recommend
antimicrobial treatment for about 14 days in most patients
[4, 6–9, 10￿]. With the paucity of new antimicrobial
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DOI 10.1007/s11908-011-0211-yclasses in development, it is increasingly important to
develop strategies to maintain or even increase the
effectiveness of the available agents. Dose and regimen
optimization represents one such strategy. Antimicro-
bials are associated with considerable side effects (eg
Clostridium difficile infection with the use of fluoroqui-
nolones) [11–13]. Moreover, longer duration of antimi-
crobial therapy with consequently selecting pressure on
gut flora might lead to an enhanced risk of the selection
of resistant strains [14]. In this respect, it is questionable
whether the benefit of antimicrobial therapy for at least
14 days at the end of treatment still outweighs its
potential side effects.
This review highlights the main research findings on
treatment duration of community-acquired febrile UTI in
non-pregnant adults. A summary of the pivotal studies
among antimicrobial treatment duration of adults with
febrile UTI is given in Table 1.
Febrile UTI in Women
The majority of UTIs in women are community-acquired
uncomplicated cystitis that usually responds to a 3-day
course of empiric antimicrobials. However, if UTIs are
accompanied by fever, another treatment regimen will be
required. Treatment guidelines for febrile UTI often only
discuss acute uncomplicated pyelonephritis, defined as
acute pyelonephritis in premenopausal, non-pregnant and
otherwise healthy women without any comorbidity [4].
Although febrile UTI is a relatively common and poten-
tially serious infection even in young women, few
controlled trials have been conducted to define optimal
therapy directly comparing the same drug given for
different durations of therapy, though a number of pub-
lications compared various treatment durations between
different antimicrobial agents. In one open label, single
center randomized trial comparing 2 versus 6 weeks of oral
therapy with trimethoprim-sulfamethoxazole or ampicillin
in 60 women with acute uncomplicated pyelonephritis,
2-week therapy was as effective as 6-week therapy with
either drug. However, shorter duration of treatment
resulted in fewer adverse effects, less frequent selection
of resistant strains, and lower costs [15]. Trimethoprim-
sulfamethoxazole was more effective than ampicillin due
to more ampicillin-resistant strains and increased recur-
rence rate in ampicillin treated patients, even with
susceptible strains. With ampicillin resistance in E. coli
exceeding 50% in many countries worldwide, ampicillin
should not be used as empirical treatment of febrile UTI.
Nitrofurantoin should not be used for the treatment of
febrile UTI because it does not achieve reliable tissue or
serum levels [16].
Trimethoprim-Sulfamethoxazole and Fluoroquinolones
Talan and colleagues [17] showed that even therapy
duration less than 14 days is effective in young, healthy
women. This double-blind, multicenter randomized con-
trolled trial compared a 7-day regimen of oral ciprofloxacin
500 mg twice daily with a 14-day regimen of trimethoprim-
sulfamethoxazole 160/800 mg twice daily for treatment of
otherwise healthy women with mild to moderate pyelone-
phritis. An initial intravenous 1-g dose of ceftriaxone in the
trimethoprim-sulfamethoxazole group or a 400-mg intrave-
nous dose of ciprofloxacin in the ciprofloxacin group was
allowed at the discretion of the doctor. At the 4–11 days
post-therapy visit, ciprofloxacin had significantly higher
microbiological (99% vs 89%, respectively) and clinical
(96% vs 83%, respectively) cure rates, regardless of
whether an initial intravenous dose of ciprofloxacin was
given. Among trimethoprim-sulfamethoxazole-treated
women, microbiological eradication and clinical cure rates
were significantly lower in women with a trimethoprim-
sulfamethoxazole-resistant strain compared with those with
a susceptible one. However, an initial intravenous dose of
ceftriaxone significantly improved microbiological cure rate
and moderately improved clinical cure rate in women with
a trimethoprim-sulfamethoxazole-resistant uropathogen.
Bacteremia (all E. coli) was present in 5.5% of the patients;
2/10 trimethoprim-sulfamethoxazole-treated subjects had
bacteriologic persistence, all four ciprofloxacin-treated
subjects achieved bacteriologic cure.
Additional evidence for a 1 week regimen of fluoroqui-
nolones as effective and safe treatment for healthy young
women was provided by two other articles, describing the
same study [18, 19]. This double blind, randomized
multicenter trial included both men and women with
complicated UTI (without fever) and acute pyelonephritis
(20% to 30%). Subgroup analysis of data about acute
pyelonephritis [18] lend additional support that an oral 5-
day regimen of a once-daily fluoroquinolone (levofloxacin
750 mg) or a 10-day regimen of ciprofloxacin 500 mg twice
daily (in 6.1% after initial intravenous ciprofloxacin
400 mg twice daily) might be effective for mild to moderate
febrile UTI, even in those with bacteremia or complicating
factors like obstruction or presence of a urinary catheter.
Another pyelonephritis study in hospitalized men and
women [20], prospectively comparing 10 days of norflox-
acin 400 mg twice daily with 10 days of ceftibuten 200 mg
twice daily, after receiving intravenous cefuroxime for 2–
4 days in each group prior to randomization to the study
drug, showed excellent clinical and bacteriological cure
rates in both groups and lower bacterial relapse rates in
patients treated with norfloxacin. The finding that a 1 week
regimen of fluoroquinolones is both efficacious and safe for
treatment of mild to moderate febrile UTI was further
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Curr Infect Dis Rep (2011) 13:571–578 573supported by a randomized comparative study demonstrat-
ing similar outcomes in comparing levofloxacin 250 mg
once daily, ciprofloxacin 500 mg twice daily and lome-
floxacin 400 mg once daily, although in severe, invasive
infections such a low dose of levofloxacin may result in
marginal tissue and blood concentrations [21]. So, in
regions with an acceptable low level of resistance to
fluoroquinolones, this class of antimicrobials represents
the preferred agents for empirical oral treatment of febrile
UTI. With increasing rate of fluoroquinolone resistance in
the last decade, the question raises at which threshold of
resistance prevalence we should switch to an alternative
agent for empirical treatment. Since clinical and bacterial
outcomes with different levels of resistance are not well
studied, the recommended threshold of 10% fluoroquino-
lone resistance prevalence is mainly based on expert
opinion [4]. For some areas in the world, the prevalence
of fluoroquinolone resistance is >10% [22, 23]. Some
experts advocate giving an initial dose of a long-acting
parenteral antimicrobial, such as a 1-g dose of ceftriaxone
or a consolidated 24-hour dose of an aminoglycoside (eg
one 5–7 mg/kg dose of gentamicin) in such situation [4].
Oral β-Lactams in Women with Febrile UTI
T h ed a t af r o mC r o n b e r ge ta l .[ 20] suggest inferior
microbiological efficacy of oral cephalosporins compared
with the fluoroquinolones, consistent with another Swedish
study [24]. To our knowledge, there are no published
studies on the efficacy of amoxicillin-clavulanate in the
treatment of febrile UTI compared to trimethoprim-
sulfamethoxazole or a fluoroquinolone. However, a
single-blind randomized trial in women with acute
uncomplicated cystitis comparing a 3-day oral regimen
of amoxicillin-clavulanate 500/125 mg twice daily with
ciprofloxacin 250 mg twice daily showed remarkable
inferior clinical (60% and 77%, respectively) and micro-
biological (76% and 95%, respectively) cure rates in the
amoxicillin-clavulanate-treated group, even in women
infected with susceptible strains (60% in resistant versus
77% in susceptible strains). Most likely, the inferiority of
β-lactams in the treatment of UTI is related to the lower
rate of eradication of E. coli from the vagina in the
amoxicillin-clavulanate group, maintaining a vaginal
reservoir for infection [25]. Although not proven, these
data are suggestive of an inferior efficacy of amoxicillin-
clavulanate in febrile UTI.
Optimal Treatment Duration in Young, Otherwise Healthy
Women
To summarize the above data regarding treatment duration
of febrile UTI in young, non-pregnant women without
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nolone is both efficacious and safe in mild to moderate
febrile UTI, given their superior clinical and bacterio-
logical cure rates [17–19]. However, emerging fluoro-
quinolone resistance will possibly necessitate an initial
dose of long-acting parenteral antimicrobial, such as a 1-g
dose of ceftriaxone or a consolidated 24-h dose of an
aminoglycoside [4]. Trimethoprim-sulfamethoxazole is
also highly efficacious in febrile UTI if caused by a
trimethoprim-sulfamethoxaxole-susceptible uropathogen
[15] but current high rates of resistance to trimethoprim-
sulfamethoxazole in many countries with corresponding
failure rates for resistant strains make this agent an
inferior choice for empirical therapy. When used empir-
ically, combination with an initial intravenous dose of
ceftriaxone resulted in improved bacteriological and
clinical cure rates [17]. When the uropathogen is
susceptible, current evidence support a 14-day regimen
[17]; shorter treatment duration has never been well
investigated. Oral β-lactams are likely less effective
compared with fluoroquinolones and trimethoprim-
sulfamethoxazole [15, 20, 24, 25]. When used, a total
course of 10–14 days of therapy is recommended [4, 9,
10￿, 26]. Probably, the same recommendations for
treatment duration apply when the antimicrobial therapy
was initially started intravenously (eg, in case of severe
sepsis or inability to take oral medication).
What Do the Guidelines Say?
The above findings and treatment recommendations are in
line with the recently updated IDSA-guideline [4]. The
European Association of Urology (EAU) guideline recom-
mends treating febrile UTI in premenopausal, otherwise
healthy women with levofloxacin 750 mg once daily for
5 days or ciprofloxacin 500 mg twice daily for 7–10 days; a
14-day regimen is advised for all other oral antimicrobials
and in all other febrile UTI patients [10￿]. However, the
guideline of the American College of Obstetricians and
Gynaecologists (ACOG) recommends treating febrile UTI
in all women (both pre and postmenopausal) for 14 days;
fluoroquinolones are considered first line oral therapy and,
in areas where resistance rates are “low,” trimethoprim-
sulfamethoxazole is an acceptable alternative [9]. The
guideline of the Dutch College of General Practitioners on
the management of UTI recommends for outpatient
treatment of adult patients with signs of tissue invasion,
including fever, an oral regimen of either amoxicillin-
clavulanate 500/125 mg three times a day, trimethoprim-
sulfamethoxazole 160/800 mg twice daily, or a fluoroqui-
nolone (eg norfloxacin 400 mg twice daily or ciprofloxacin
500 mg twice daily) for 10 days [26].
Febrile UTI in “Complicated” Patients
While treatment recommendations of febrile UTI are quite
straightforward in young, healthy, non-pregnant women
with short oral antimicrobial courses on an outpatient basis
(provided they are able to take oral medication and have no
severe sepsis), there is a lack of conformity on therapeutic
approaches for other (sometimes referred as “complicated”)
categories of febrile UTI patients, like men, postmenopaus-
al women, the elderly, or patients with urological abnor-
malities or indwelling urinary catheter. Oral antimicrobial
treatment regimens and optimal treatment duration have
hardly been studied in the latter categories. Most studies
focus exclusively on febrile UTI in young, healthy
women, or consist of a very heterogeneous study population
with both women and men of all ages and a broad range of
comorbidities, reducing the power and making subgroup
analysis sometimes hardly to perform. There are no published
trials specifically conceived to delineate optimal treatment
duration in those categories, except for men. Currently, a
randomized placebo-controlled study comparing a 7 to14day
of antimicrobial therapy in consecutive patients with febrile
UTI is ongoing to provide evidence within this category of
“complicated”[27]. The results of this study are expected to
become available in 2012.
Febrile UTI in Men
UTI is very uncommon in otherwise healthy, young and
middle-aged men. A Norwegian study [28] reported an
estimated annual incidence of 6–8 UTIs per 10,000 men
aged 21–50 years. Incidence increases with age because of
urological abnormalities and instrumentation. Since more
than 90% of men with febrile UTI have a concomitant
infection of the prostate, as measured by transient increases in
serum PSA and prostate volume,[29] the goal of treatment is
not only to sterilize the urine but also to reach sufficient
antimicrobial concentration in the prostate. Therefore, anti-
microbials reaching free concentrations in prostatic fluid and
prostatic tissue that exceed the minimum inhibitory
concentrations of most common causative bacteria
should be chosen for therapy. Fluoroquinolones have
such favourable pharmacokinetic properties and antibac-
terial spectra [30]. Trimethoprim also achieves adequate
concentrations in the prostate and is an alternative to
fluoroquinolones provided the bacteria are susceptible to
this antimicrobial [31]. As described earlier in this article
and demonstrated in some mixed trials with a minority of
men, therapy with β-lactams may result in lower cure
rates in men with febrile UTI [20, 24].
There is an apparent lack of studies on optimal treatment
duration of febrile UTI in men. We only found one study
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[32]. In this open, prospective and randomized trial, 72 men
with community-acquired febrile UTI (without a chronic
indwelling catheter) were treated with ciprofloxacin 500 mg
twice daily for 2 or 4 weeks. All responded successfully
with resolution of fever and symptoms. There was no
significant difference in bacteriological cure rate 2 weeks
post-treatment between patients treated for 2 or 4 weeks
(89% versus 97%, 95% CI for difference in proportions −3%
to 19%), nor after 1 year (59% versus 76%, 95% CI −5% to
39%). The cumulative clinical cure rate after 1 year was 72%
and 82%, respectively (95% CI −10% to 30%). Recurrences
after 1 year comprised asymptomatic bacteriuria (48%),
symptomatic lower UTI (23%), and another episode of
febrile UTI (29%). A tendency toward more recurrences
in the 2-week group could be attributed to a larger
proportion of men with urological lesions requiring
surgical interventions (26% versus 12%) in that group.
The results should be interpreted with some caution,
given the wide confidence interval for the differences in
cure rate, but this study suggests a 2-week course of
ciprofloxacin 500 mg twice daily may be an adequate
treatment for febrile UTI in men.
Another Swedish study lent additional support for a 2-week
regimen of oral fluoroquinolones in men [24]. In this
randomized, double-blind trial, adult men and women with a
presumptive diagnosis of acute pyelonephritis (defined as
febrile UTI) were randomly assigned to receive a 14-day
course of oral treatment with either norfloxacin 400 mg twice
daily or cefadroxil 1 g twice daily. Of 197 patients enrolled,
16 (29.5%) men were treated with norfloxacin and 12 (21.1%)
with cefadroxil. In this subgroup, a 14-day regimen of
norfloxacin was highly effective, regardless of the presence
of bacteremia or complicating factors such as diabetes mellitus
or urinary tract abnormalities, with significantly higher
bacteriological cure rate than with cefadroxil, both at 3–
10 days (100% versus 73%, respectively) and up to 2 months
after cessation of treatment (88% versus 75%, respectively).
ThesameresultsinmenwereobtainedfromathirdSwedish
trial, [20] which used step-down treatment; initial intravenous
treatment with cefuroxime was followed by either norfloxacin
400 mg twice daily or ceftibuten 200 mg twice daily for
10 days. Thus, these studies provided evidence that men with
mild to moderate febrile UTI may be safely treated at home
with a 14 days regimen of an oral fluoroquinolone.
Febrile UTI in the Elderly and Patients
with Comorbidities
Oral ciprofloxacin has a high bioavailability and a broad
spectrum of activity against uropathogens. Therefore,
Mombelli and colleagues [33] analyzed the efficacy of
ciprofloxacin in the empirical management of severe febrile
UTIs. In a multicenter prospective randomized study,
patients with serious (including febrile) UTI were random-
ized in the hospital setting to empirical antibiotic treatment
with ciprofloxacin received either orally or intravenously.
Excluded were patients with severe sepsis, inability to take
oral medication or renal obstructive disease. In this study,
141 patients participated; 39% were men, 42 had co-
morbidity (eg diabetes mellitus) and 35% had bacteremia.
There were no infection-related deaths and no patients
required an early change of antibiotics because of worsen-
ing clinical status during the initial empirical phase of
treatment. The rates of microbiological failure (3% in the
oral versus 2% in the intravenous treatment group) and of
unsatisfactory clinical response (4% oral versus 3%
intravenous) were low. A treatment change was eventually
required in 14% of the patients assigned to the oral and 7%
of the patients assigned to the intravenous regimen, mainly
because of the isolation of enterococci or ciprofloxacin-
resistant organisms in pretherapy urine specimens. There
were no differences in outcome between the two regimens
in premenopausal versus postmenopausal women. Unfortu-
nately, treatment duration in both groups was not stated.
The authors concluded that in the hospital setting, oral
ciprofloxacin is as effective as the intravenous regimen in
the initial empirical treatment of serious UTI, including the
bacteremic form. They hypothesize the oral regimen can be
used for outpatient treatment even in serious UTI. Our own
study among primary health care centers (PHCs) and
emergency departments (EDs) supported this hypothesis
[34￿]. We performed a prospective observational cohort
study including consecutive non-pregnant adults with
febrile UTI. Of 395 evaluable patients, 153 were recruited
by their GP and treated as outpatients; 146 (95%) patients
received oral ciprofloxacin 500 mg twice daily for 10–
14 days. The remaining 242 patients were recruited at EDs
of which 35 (14%) were treated as outpatients with oral
ciprofloxacin and 207 (86%) were admitted and empirically
treated with cefuroxime ± gentamicin. Median age was
63 years [IQR 42–77], 34% were male and 58% had
comorbidity, all characteristics comparable between both
groups. Bacteremia was present in 10% of the outpatients
and 27% of the inpatients. During follow-up, 8 (5%) of
PHC group were hospitalized because of suspected
deteriorating sepsis, progressive illness, or persistent
symptoms; none of them required ICU-admission, nor
were there any attributable deaths. Clinical cure rates at
30 days were high in both groups (90% in PHC and
89% in ED-group, respectively) and persistent at least
until 3 months follow-up. Bacteriological outcomes were
not reported. Thus, the outcome of patients treated with
oral ciprofloxacin on an outpatient basis suggests that
among selected adults with febrile UTI, many can be
576 Curr Infect Dis Rep (2011) 13:571–578safely treated at home using a 10–14 day regimen of
oral fluoroquinolones, including men, the elderly, and
patients with comorbidity or bacteremia.
Besides this observational study, there is remarkably little
evidence in the literature regarding the optimal treatment
duration of febrile UTI in the elderly or patients with
comorbiditylikediabetesmellitusorurologicalabnormalities,
despite high prevalence, since most randomized trials have
excluded patients with underlying systemic illnesses or
urinary tract abnormalities. Current treatment durations are
mainly based on expert opinion; recommendations often do
not differ from that in non-diabetic, young and otherwise
healthy patients [4, 9, 10, 35]. Therefore, randomized
therapeutic trials to define the optimal treatment duration in
these patient categories are urgently needed.
Cather-Related Febrile UTI
A substantial part of the UTIs in elderly is catheter-related,
but also in patients of any age with catheter-related febrile
UTI it is not well known what the optimal duration of
treatment is. We found one trial prospectively comparing
treatment with either a parenteral aminoglycoside or oral
ciprofloxacin 500 mg twice daily for 7–10 days in
catheterized patients in a chronic care facility with
complicated UTI (58.5% febrile UTI) and urinary tract
abnormalities (eg neurogenic bladder, obstruction), the
majority being men [36]. Whether the urinary catheter has
been replaced before start of treatment was not described.
Clinical cure 5–9 days post-therapy was about 80% in both
groups, and 69% versus 58% 28–30 days post-therapy in the
ciprofloxacin and aminoglycoside group, respectively. Bacte-
riological cure, defined as sterile urine culture, was achieved
in the ciprofloxacin and aminoglycoside group in 63% and
15% 2–5 days after first dose and in 21% and 23% 5–9d a y s
post-therapy, respectively. This trial, which is quite difficult to
interpret because of uncertainty about catheter replacement
beforestarttreatment,suggeststhatciprofloxacin7–10daysat
least clinically might be sufficient for treating catheter-related
febrile UTI in men but more studies are needed to further
explore this observation.
Conclusions
Based on the current evidence in the literature (Table 1), we
conclude that premenopausal, non-pregnant and otherwise
healthy women can be treated orally with 5–7d a y so f
adequately dosed fluoroquinolones or, if proven susceptible
to the urinary isolate, with 14 days of trimethoprim-
sulfamethoxazole. Oral β-lactams are probably less effective
in comparison with fluoroquinolones and trimethoprim-
sulfamethoxazole. In all other patients with febrile UTI,
optimal treatment duration is still unknown and should,
awaiting randomized controlled trials, probably be at least
14 days. Although approximately 10% of patients with
uncomplicated febrile UTI have bacteremia, there is no
evidence that bacteremia has prognostic significance or
warrants longer therapy in an otherwise healthy individual
when using an antibiotic regimen ensuring adequate tissue
and blood concentrations.
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